Prelude Capital Management’s iRadimed IRMD Stock Holding History

Prelude Capital Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-400	Closed	-$9K	–	2099
2020 Q1	$9K	Sell	400 -200	-33%	-$4.76K	﹤0.01%	1144
2019 Q4	$14K	Buy	+600	New	+$14K	﹤0.01%	1651
2019 Q2	–	Sell	-301	Closed	-$8K	–	1889
2019 Q1	$8K	Hold	301	–	–	﹤0.01%	1521
2018 Q4	$7K	Buy	+301	New	+$8.09K	﹤0.01%	1468
2018 Q3	–	Sell	-300	Closed	-$6K	–	1872
2018 Q2	$6K	Buy	+300	New	+$5.3K	﹤0.01%	1548
2018 Q1	–	Sell	-6,500	Closed	-$98K	–	1611
2017 Q4	$98K	Buy	+6,500	New	+$82.6K	0.01%	791
2016 Q1	–	Sell	-829	Closed	-$23K	–	1388
2015 Q4	$23K	Buy	+829	New	+$23.4K	﹤0.01%	1180
2014 Q4	–	Sell	-4,000	Closed	-$28K	–	2019
2014 Q3	$28K	Buy	+4,000	New	+$36.2K	﹤0.01%	1664

Other funds holding IRMD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

RCMC

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Prelude Capital Management's IRMD Position: Q2 2020 in Review

Prelude Capital Management sold out of iRadimed (IRMD) in Q2 2020, closing a stake of 400 shares — an estimated $9K sold.

Prelude Capital Management first reported a position in IRMD in Q3 2014 and held it in 8 quarters. The position peaked at $98K in Q4 2017. 65 funds tracked by Wall St. Rank hold IRMD as of Q2 2020.

Prelude Capital Management reported no remaining iRadimed position as of Q2 2020 after selling out during the quarter.
Prelude Capital Management sold 400 iRadimed shares in Q2 2020, an estimated $9K.
Prelude Capital Management first reported a position in iRadimed in Q3 2014 and held it in 8 quarters.
Prelude Capital Management's iRadimed position peaked at $98K in Q4 2017.
65 funds tracked by Wall St. Rank held iRadimed as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.